IN2012DN01132A - - Google Patents
Info
- Publication number
- IN2012DN01132A IN2012DN01132A IN1132DEN2012A IN2012DN01132A IN 2012DN01132 A IN2012DN01132 A IN 2012DN01132A IN 1132DEN2012 A IN1132DEN2012 A IN 1132DEN2012A IN 2012DN01132 A IN2012DN01132 A IN 2012DN01132A
- Authority
- IN
- India
- Prior art keywords
- compounds
- present
- preparation
- formula
- cholesterol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 238000002360 preparation method Methods 0.000 abstract 3
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101628888A CN101993403B (zh) | 2009-08-11 | 2009-08-11 | 氮杂环丁酮类化合物及医药应用 |
| PCT/CN2010/001206 WO2011017907A1 (zh) | 2009-08-11 | 2010-08-09 | 氮杂环丁酮类化合物及医药应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01132A true IN2012DN01132A (es) | 2015-04-10 |
Family
ID=43585888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1132DEN2012 IN2012DN01132A (es) | 2009-08-11 | 2010-08-09 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8623855B2 (es) |
| EP (1) | EP2465847B1 (es) |
| JP (1) | JP5706896B2 (es) |
| KR (1) | KR101394993B1 (es) |
| CN (2) | CN101993403B (es) |
| CA (1) | CA2770793C (es) |
| CL (1) | CL2012000351A1 (es) |
| EA (1) | EA021484B1 (es) |
| IL (1) | IL218045A (es) |
| IN (1) | IN2012DN01132A (es) |
| MX (1) | MX2012001829A (es) |
| MY (1) | MY157237A (es) |
| NZ (1) | NZ598050A (es) |
| PE (1) | PE20121086A1 (es) |
| SG (1) | SG178313A1 (es) |
| UA (1) | UA105053C2 (es) |
| WO (1) | WO2011017907A1 (es) |
| ZA (1) | ZA201201676B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101993403B (zh) * | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
| HK1210143A1 (en) * | 2012-09-05 | 2016-04-15 | 浙江海正药业股份有限公司 | Crystal forms of azetidinone compounds and preparing methods thereof |
| CN104780918B (zh) * | 2013-03-01 | 2017-03-08 | 浙江海正药业股份有限公司 | 用于预防和/或治疗丙型肝炎的氮杂环丁酮化合物及其组合物 |
| CN105294426B (zh) * | 2014-06-09 | 2019-05-14 | 浙江海正药业股份有限公司 | 氮杂环丁酮化合物制备方法及其中间体 |
| WO2019101150A1 (zh) * | 2017-11-23 | 2019-05-31 | 浙江海正药业股份有限公司 | 一种海泽麦布片剂及其制备方法 |
| WO2019101151A1 (zh) * | 2017-11-23 | 2019-05-31 | 浙江海正药业股份有限公司 | 一种海泽麦布和HMG-CoA还原酶抑制剂的药物组合物 |
| WO2022262768A1 (zh) * | 2021-06-17 | 2022-12-22 | 浙江海正药业股份有限公司 | 海泽麦布中间体及其制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2525125B2 (ja) | 1991-07-23 | 1996-08-14 | シェリング・コーポレーション | 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法 |
| LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5627176A (en) | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| CA2191455A1 (en) | 1994-06-20 | 1995-12-28 | Wayne Vaccaro | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| EP0877750B1 (en) | 1995-10-31 | 2002-06-19 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents |
| US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| ES2287826T3 (es) | 2000-12-20 | 2007-12-16 | Schering Corp | 2-azetidinonas sustituidas con hidroxi utiles como agentes hipocolesterolemicos. |
| IL156552A0 (en) | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| EP1345895B1 (de) | 2000-12-21 | 2006-12-27 | Sanofi-Aventis Deutschland GmbH | Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen |
| MXPA03005019A (es) | 2000-12-21 | 2003-09-25 | Avantis Pharma Deutschland Gmb | Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos y su uso. |
| TWI291957B (en) * | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| DE10227507A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE10227506A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE10227508A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| TW200726746A (en) * | 2005-05-06 | 2007-07-16 | Microbia Inc | Processes for production of 4-biphenylylazetidin-2-ones |
| US7696177B2 (en) * | 2005-06-15 | 2010-04-13 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| CN101134739A (zh) * | 2006-09-01 | 2008-03-05 | 长春吉大天元化学技术股份有限公司 | 新的β-内酰胺类化合物及其制备方法及其药物用途 |
| WO2008057948A2 (en) * | 2006-11-01 | 2008-05-15 | Ironwood Pharmaceuticals, Inc. | Processes for production of diphenylylazetidin-2-ones and related compounds |
| US20080280836A1 (en) * | 2007-05-08 | 2008-11-13 | Morriello Gregori J | Anti-hypercholesterolemic biaryl azetidinone compounds |
| CN101423511A (zh) * | 2007-11-05 | 2009-05-06 | 中山奕安泰医药科技有限公司 | 依泽替米贝中间体及依泽替米贝的合成方法 |
| CN101993403B (zh) * | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
-
2009
- 2009-08-11 CN CN2009101628888A patent/CN101993403B/zh active Active
-
2010
- 2010-08-09 IN IN1132DEN2012 patent/IN2012DN01132A/en unknown
- 2010-08-09 KR KR1020127004728A patent/KR101394993B1/ko active Active
- 2010-08-09 CN CN201080035472.0A patent/CN102448932B/zh active Active
- 2010-08-09 JP JP2012524081A patent/JP5706896B2/ja active Active
- 2010-08-09 US US13/389,932 patent/US8623855B2/en active Active
- 2010-08-09 UA UAA201202735A patent/UA105053C2/uk unknown
- 2010-08-09 WO PCT/CN2010/001206 patent/WO2011017907A1/zh not_active Ceased
- 2010-08-09 SG SG2012008660A patent/SG178313A1/en unknown
- 2010-08-09 EP EP10807852.8A patent/EP2465847B1/en active Active
- 2010-08-09 EA EA201270248A patent/EA021484B1/ru not_active IP Right Cessation
- 2010-08-09 PE PE2012000185A patent/PE20121086A1/es active IP Right Grant
- 2010-08-09 CA CA2770793A patent/CA2770793C/en active Active
- 2010-08-09 MX MX2012001829A patent/MX2012001829A/es active IP Right Grant
- 2010-08-09 NZ NZ598050A patent/NZ598050A/xx not_active IP Right Cessation
- 2010-08-09 MY MYPI2012000578A patent/MY157237A/en unknown
-
2012
- 2012-02-09 IL IL218045A patent/IL218045A/en not_active IP Right Cessation
- 2012-02-10 CL CL2012000351A patent/CL2012000351A1/es unknown
- 2012-03-07 ZA ZA2012/01676A patent/ZA201201676B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY157237A (en) | 2016-05-13 |
| US20120208994A1 (en) | 2012-08-16 |
| EP2465847A4 (en) | 2013-04-17 |
| WO2011017907A1 (zh) | 2011-02-17 |
| IL218045A (en) | 2017-05-29 |
| KR101394993B1 (ko) | 2014-05-15 |
| AU2010282097A1 (en) | 2012-04-05 |
| PE20121086A1 (es) | 2012-08-17 |
| JP5706896B2 (ja) | 2015-04-22 |
| EA201270248A1 (ru) | 2012-07-30 |
| CA2770793C (en) | 2017-06-13 |
| ZA201201676B (en) | 2012-11-28 |
| CN101993403B (zh) | 2012-07-11 |
| CA2770793A1 (en) | 2011-02-17 |
| US8623855B2 (en) | 2014-01-07 |
| EA021484B1 (ru) | 2015-06-30 |
| IL218045A0 (en) | 2012-04-30 |
| EP2465847A1 (en) | 2012-06-20 |
| CL2012000351A1 (es) | 2012-08-10 |
| SG178313A1 (en) | 2012-03-29 |
| MX2012001829A (es) | 2012-07-23 |
| UA105053C2 (uk) | 2014-04-10 |
| CN101993403A (zh) | 2011-03-30 |
| CN102448932B (zh) | 2014-08-13 |
| NZ598050A (en) | 2013-03-28 |
| CN102448932A (zh) | 2012-05-09 |
| JP2013501734A (ja) | 2013-01-17 |
| KR20120047969A (ko) | 2012-05-14 |
| EP2465847B1 (en) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN01132A (es) | ||
| EA200900741A1 (ru) | Способы лечения гиперхолестеринемии | |
| TN2015000084A1 (fr) | Pyridinones bicycliques nouvelles | |
| EP2440212A4 (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CORONARY DISEASE | |
| MX2012002633A (es) | Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes. | |
| JO2870B1 (en) | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes | |
| PE20120055A1 (es) | (1-fenil-2-piridin-4-il)etil esteres del acido benzoico como inhibidores de fosfodiesterasa | |
| IL194975A0 (en) | Composition and methods for treatment of congestive heart failure | |
| WO2010093727A8 (en) | Quinazolinones as prolyl hydroxylase inhibitors | |
| WO2011014661A3 (en) | Liver x receptor agonists | |
| MX2019005130A (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente. | |
| TR201909777T4 (tr) | Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar | |
| NO20091560L (no) | Biaryleterureaforbindelser | |
| MX2010009922A (es) | Activadores de piridazinona glucocinasa. | |
| MX2011009493A (es) | Compuestos para el tratamiento de trastornos metabolicos. | |
| BR112012020704A2 (pt) | compostos de pirrolopirimidina deuterados como inibidores de cdk4/6 | |
| CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
| JO2939B1 (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
| MY169485A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| EA201070187A1 (ru) | Модифицированные ферменты лецитин-холестерин ацилтрансферазы | |
| MX2012006822A (es) | 1,7-diazacarbazoles y metodos de uso. | |
| NZ615578A (en) | Pyridopyrazine derivatives and their use | |
| TN2012000418A1 (en) | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | |
| MY150745A (en) | Isoserine derivatives for use as coagulation factor ixa inhibitors | |
| GEP20125570B (en) | Use of indazolemethoxyalkanoic acid for reducing levels of triglycerides, cholesterol and glucose |